Schroder UK Public Private Trust plc
SUPP.L
London Stock Exchange- -
GBp
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Schroder UK Public Private Trust plc (SUPP.L) is a UK-listed closed-end investment trust that seeks long-term capital growth by investing in a diversified portfolio of publicly listed and unquoted companies, primarily those showcasing innovative British businesses in sectors such as biotechnology, life sciences, technology, fintech, and advanced engineering. The trust allocates across public equities, including Oxford Nanopore Technologies (next-generation DNA sequencing), Immunocore (T cell receptor therapies), Genomics plc, and IDEX Biometrics (fingerprint authentication); and private companies such as Atom Bank (mobile banking services including savings, mortgages, and loans), BenevolentAI (AI-driven drug discovery), Reaction Engines (SABRE engine for hypersonic and space travel), AMO Pharma (therapies for rare neurogenetic disorders), Seedrs (crowdfunding platform), HP Environmental Technologies Fund (environmental tech investments), and Revolut (global neobank superapp). Managed by Schroder Investment Management Limited, with private equity investments led by Tim Creed, Head of Private Equity Investments at Schroders Capital, the trust targets high-growth opportunities with strong management teams, organic growth focus, and optimal risk-reward profiles; it operates primarily in the UK market with some international exposure through portfolio holdings. Founded in 2015 and headquartered at 1 London Wall Place, London, EC2Y 5AU, the company was originally incorporated as Woodford Patient Capital Trust plc, renamed Schroder UK Public Private Trust plc in December 2019 following a management transition from Woodford Investment Management, and briefly rebranded as Schroders Capital Global Innovation Trust plc in 2022 before reverting. Recent major developments include a January 2021 secondary portfolio sale of seven life sciences assets to Rosetta Capital for £49.0 million, establishing co-shareholder relationships in companies like ReNeuron, Immunocore, and Inivata, with follow-on capital commitments; portfolio rebalancing through private sales realizing £120.6 million in the half-year to June 2021; full repayment of its bank loan, strengthening the balance sheet with net current assets rising to £27.4 million by mid-2021; and ongoing evolution of holdings as of June 2022 to emphasize innovative UK leaders, reflecting strategic shifts toward sustainable value creation amid market volatility.